Wells Fargo & Company Synthetic Biologics, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$1.9 - $2.9 $469 - $716	247 Added 30.38%	1,060 $0
Q1 2022 May 16, 2022	BUY	$2.3 - $4.3 $6 - $12	3 Added 0.37%	813 $0
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.5 $2 - $4	1 Added 0.12%	810 $0
Q3 2021 Nov 15, 2021	SELL	$4.3 - $5.8 $172 - $232	-40 Reduced 4.71%	809 $0
Q2 2021 Aug 16, 2021	BUY	$4.6 - $7.2 $41 - $64	9 Added 1.07%	849 $1,000

Q1 2021 May 13, 2021	BUY	$5.0 - $11.7 $3,550 - $8,307	710 Added 546.15%	840 $1,000
Q4 2020 Feb 09, 2021	BUY	$2.9 - $4.6 $31 - $50	11 Added 9.24%	130 $0
Q3 2020 Nov 05, 2020	BUY	$4.5 - $7.1 $27 - $42	6 Added 5.31%	119 $0
Q2 2020 Aug 13, 2020	SELL	$2.8 - $5.7 $39 - $79	-14 Reduced 11.02%	113 $0
Q1 2020 May 14, 2020	BUY	$2.7 - $6.1 $342 - $774	127 New	127 $0

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.